MedPath

KWANG DONG PHARMACEUTICAL CO., LTD.

KWANG DONG PHARMACEUTICAL CO., LTD. logo
🇹🇼Taiwan
Ownership
Public
Established
1963-01-01
Employees
1K
Market Cap
-
Website
http://www.ekdp.com

Clinical Trials

6

Active:0
Completed:5

Trial Phases

4 Phases

Phase 1:2
Phase 2:1
Phase 3:2
+1 more phases

Drug Approvals

2

PHILIPPINES:2

Drug Approvals

Atrozole

Approval Date
Jul 14, 2025
PHILIPPINES

Anazdex

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (33.3%)
Phase 3
2 (33.3%)
Phase 2
1 (16.7%)
Phase 4
1 (16.7%)

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Drug: Placebo
First Posted Date
2021-06-29
Last Posted Date
2024-11-13
Lead Sponsor
Kwang Dong Pharmaceutical co., ltd.
Target Recruit Count
193
Registration Number
NCT04943068
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency

Phase 4
Completed
Conditions
Vitamin D Deficiency
Interventions
Drug: Vitamin D3 B.O.N. Injection
First Posted Date
2017-07-28
Last Posted Date
2017-07-28
Lead Sponsor
Kwang Dong Pharmaceutical co., ltd.
Target Recruit Count
108
Registration Number
NCT03233295

To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects

Phase 1
Conditions
Obesity
Interventions
Drug: placebo
First Posted Date
2015-06-03
Last Posted Date
2015-06-03
Lead Sponsor
Kwang Dong Pharmaceutical co., ltd.
Target Recruit Count
38
Registration Number
NCT02462031
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency

Phase 3
Completed
Conditions
Vitamin D Deficiency
Interventions
Drug: Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)
Drug: Placebo
First Posted Date
2015-05-13
Last Posted Date
2016-07-27
Lead Sponsor
Kwang Dong Pharmaceutical co., ltd.
Target Recruit Count
84
Registration Number
NCT02443246

Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects

Phase 1
Completed
Conditions
Drug Toxicity
Interventions
Drug: placebo
First Posted Date
2013-11-08
Last Posted Date
2014-08-12
Lead Sponsor
Kwang Dong Pharmaceutical co., ltd.
Target Recruit Count
40
Registration Number
NCT01979380
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.